Grünenthal, a global leader in pain management and related diseases, has announced the appointment of Prof. Dr. Uli Brödl as Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective February 1st, 2025.
Brödl brings with him over 15 years of industry experience, having previously served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim’s Venture Fund Investment Committee at Boehringer Ingelheim. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Brödl also has extensive market experience, having led Boehringer Ingelheim’s Canadian medical organization and founded the BI Canada Incubator, an innovation lab focused on developing healthcare solutions.
With a medical degree from Ludwig-Maximilians University Munich and board certifications in internal medicine and endocrinology, Brödl brings a unique combination of expertise to the role. He is also an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich.
In his new role as CSO, Brödl will be responsible for driving Grünenthal’s innovation pipeline and bringing new treatments to patients. His extensive experience in both R&D and commercial functions, combined with his passion for improving the lives of underserved patients, makes him an ideal fit for the company.
Grünenthal CEO Gabriel Baertschi expressed his excitement about Brödl joining the team, stating, “With Uli, we have been able to attract an excellent leader. His extensive experience in R&D and commercial functions combined with Uli’s drive to bring innovative medicines to patients will help us propel our vision of a world free of pain.”
Grünenthal, headquartered in Aachen, Germany, is dedicated to improving the quality of life for patients suffering from pain and related diseases. They are a science-based, fully integrated pharmaceutical company with a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Their vision is a world free of pain, and they are passionate about using innovation to make this a reality.
Grünenthal has affiliates in 27 countries across Europe, Latin America, and the U.S., with their products available in approximately 100 countries. In 2023, the company employed around 4,400 people and achieved revenues of €1.8 billion.
For more information about Grünenthal, visit their website at https://www.grunenthal.com. You can also follow them on LinkedIn at Grunenthal Group and on Instagram at grunenthal.
For further information, please contact:
Florian Dieckmann, Head Global Corporate Affairs & Communication
Tel.: +49 241 569-2555
Florian.Dieckmann@grunenthal.com
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.